bevacizumab + paclitaxel + pictilisib

This is a combination regimen of three agents: - **Bevacizumab** is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), thereby blocking angiogenesis. - **Paclitaxel** is a microtubule-stabilizing chemotherapeutic agent that disrupts cell division. - **Pictilisib** (GDC-0941) is an oral small molecule inhibitor targeting phosphatidylinositol 3-kinase (PI3K), specifically acting as a pan-class I PI3K inhibitor. The combination has been studied in phase Ib clinical trials for patients with locally recurrent or metastatic breast cancer and non-small cell lung cancer. The rationale for combining these drugs lies in their complementary mechanisms—targeting tumor vasculature, direct cytotoxicity, and inhibition of the PI3K pathway involved in tumor growth and survival. Clinical studies have shown manageable safety profiles and preliminary antitumor activity[1][2][3].

Brand names

Avastin (bevacizumab)

Other names

pictilisib + paclitaxel + bevacizumab